Los Angeles, July 8, 2015 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB:BICX), developer of the Start Fresh Program ® used for the treatment of alcohol and opioid dependence, today announced that it has retained Maxim Group LLC, a leading investment banking, securities, and investment firm, to provide strategic corporate planning and investment banking services. Maxim will focus on assisting BioCorRx in its strategies for maximizing shareholder value through its full scope of investment banking services.

BioCorRx's Interim Chief Executive Officer, Brady James Granier, states; "We look forward to working with the team at Maxim. They have tremendous experience, especially in the healthcare sector and we are ready for their assistance in executing our corporate strategy. Our primary business objective is to help families struggling with addiction and we feel we can do that more effectively once the company attracts more interest from the investment community. More work is needed to educate the public on the type of treatment we offer to struggling families, as well as to break the old paradigm of how addiction is classified and treated. Addiction treatment has evolved and we feel that Maxim can help us to be at the forefront of that evolution."

A Maxim Group representative commented, "We are looking forward to working with BioCorRx to assist with strategic planning, developing strategic partnerships, advising on potential acquisitions and introducing the company to the investment community."

Visit BioCorRx, Inc.'s investor relations website at www.BICXcorp.com to receive the most up to date company information.

Click here to view Recent National Television Media on the BioCorRx YouTube Channel

Click here for company Facebook page for more stories and media coverage

About Maxim Group LLC

Maxim Group LLC is a leading full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed income and derivative sales & trading, equity research and prime brokerage services to a diverse range of corporate clients, institutional investors and high net worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board (MSRB), and is a member of the following: Financial Industry Regulatory Authority (FINRA), Securities Insurance Protection Corporation (SIPC), NASDAQ Stock Market and NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com.

About BioCorRx, Inc

BioCorRx, Inc. ® (OTCQB: BICX) is an addiction treatment and rehabilitation company offering a unique approach to the treatment of substance abuse addiction. The Start Fresh Program®, a medication-assisted treatment program, consists of two components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. Clinic reports show that the treatment program can be successful for individuals who complete the program. For more information on BICX, visit  www.BioCorRx.com

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
CONTACT: Investor Relations                  SmallCapVoice.com, Inc.                   512-267-2430

BioCorRx logo